Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study

被引:57
|
作者
Landoni, F. [1 ]
Sartori, E. [2 ]
Maggino, T. [3 ]
Zola, P. [4 ]
Zanagnolo, V. [1 ]
Cosio, S. [5 ]
Ferrari, F. [2 ]
Piovano, E. [4 ]
Gadducci, A. [5 ]
机构
[1] European Inst Oncol, Cerv Canc Ctr, Dept Gynecol, Milan, Italy
[2] Univ Brescia, Dept Gynecol & Obstet, Brescia, Italy
[3] Umberto I Hosp, Unit Gynecol & Obstet, Venice, Italy
[4] Univ Turin, Dept Surg Sci, I-10124 Turin, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Div Obstet & Gynecol, I-56127 Pisa, Italy
关键词
Cervical cancer; Chemotherapy; Adjuvant treatment; Survival; RANDOMIZED-TRIAL; CARCINOMA; HYSTERECTOMY; IFOSFAMIDE; PACLITAXEL; MANAGEMENT; CISPLATIN;
D O I
10.1016/j.ygyno.2013.12.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Neoadjuvant chemotherapy [NACT] followed by radical hysterectomy is an alternative therapeutic option to concurrent chemotherapy-radiotherapy for locally advanced cervical cancer. However there are very few data about the effectiveness of any post-operative treatment in this clinical setting. The purpose of this study was to correlate the patterns of recurrence and the clinical outcomes of cervical cancer patients who received NACT, with postoperative adjuvant treatment. Patients and methods. This retrospective multicenter study included 333 patients with FIGO stage Ib(2)-IIb cervical cancer who underwent platinum-based NACT followed by radical surgery. Pathological responses were retrospectively assessed as complete; optimal partial; and suboptimal response. Overall optimal response rate was the sum of complete and optimal partial response rates. Results. On the whole series, recurrence-free survival was significantly longer in patients who achieved an overall optimal response than in those who did not (p < 0.0001), and in patients who received adjuvant chemotherapy compared to those who did not (p = 0.0001). On multivariate analysis, consolidation therapy (p = 0.0012) was the only independent prognostic variable for recurrence-free survival; whereas FIGO stage (p = 0.0169) and consolidation therapy (p = 0.0016) were independent prognostic variables for overall survival. Conclusion. Optimal responders after chemo-surgical treatment for FIGO stage Ib(2)-IIb cervical cancer do not need any further treatment. Additional cycles of chemotherapy could be of benefit for patients with suboptimal response and intra-cervical residual disease. Both adjuvant chemotherapy and adjuvant radiation treatments do not seem to improve the clinical outcome of patients with extra-cervical residual disease compared to no further treatment. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:611 / 617
页数:7
相关论文
共 50 条
  • [1] Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study)
    Gadducci, A.
    Sartori, E.
    Maggino, T.
    Zola, P.
    Cosio, S.
    Zizioli, V.
    Lapresa, M.
    Piovano, Elisa
    Landoni, F.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 640 - 644
  • [2] FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study
    Plante, Marie
    van Trommel, Nienke
    Lheureux, Stephanie
    Oza, Amit M.
    Wang, Lisa
    Sikorska, Karolina
    Ferguson, Sarah Elizabeth
    Han, Kathy
    Amant, Frederic
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (05) : 969 - 975
  • [3] Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer
    Gong, Lin
    Lou, Jian-Yan
    Wang, Ping
    Zhang, Jia-Wen
    Liu, Hui
    Peng, Zhi-Lan
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012, 117 (01) : 23 - 26
  • [4] Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery
    Sun, Haiying
    Huang, Kecheng
    Tang, Fangxu
    Li, Xiong
    Wang, Xiaoli
    Long, Sixiang
    Zhou, Shasha
    Suolangquzhen
    Zhang, Jianwei
    Ning, Ruoqi
    Li, Shuang
    Wang, Shixuan
    Ma, Ding
    SCIENTIFIC REPORTS, 2018, 8
  • [5] Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study
    Gadducci, Angiolo
    Landoni, Fabio
    Cosio, Stefania
    Zizioli, Valentina
    Zola, Paolo
    Ferrero, Anna Maria
    Lapresa, Maria Teresa
    Maggino, Tiziano
    Sartori, Enrico
    ANTICANCER RESEARCH, 2018, 38 (06) : 3627 - 3634
  • [6] Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study
    Kondo, Eiji
    Yoshida, Kenta
    Tabata, Tsutomu
    Kobayashi, Yoichi
    Yamagami, Wataru
    Ebina, Yasuhiko
    Kaneuchi, Masanori
    Nagase, Satoru
    Machida, Hiroko
    Mikami, Mikio
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (02)
  • [7] Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy
    Vizza, E.
    Pellegrino, A.
    Milani, R.
    Fruscio, R.
    Baiocco, E.
    Cognetti, F.
    Savarese, A.
    Tomao, F.
    Chen, C.
    Corrado, G.
    EJSO, 2011, 37 (04): : 364 - 369
  • [8] Neoadjuvant chemotherapy followed by radical surgery versus primary surgery in stage IB2-IIB cervical adenocarcinoma: a retrospective study
    Zeng, Feitianzhi
    Guo, Peng
    Xia, Meng
    He, Mian
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2023, 44 (06) : 12 - 19
  • [9] Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy
    Uegaki, Kazunori
    Shimada, Muneaki
    Sato, Seiya
    Deura, Imari
    Naniwa, Jun
    Sato, Shinya
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Harada, Tasuku
    Kigawa, Junzo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) : 348 - 353
  • [10] Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-Irinotecan and platinum chemotherapy
    Matsumura, Maki
    Takeshima, Nobuhiro
    Ota, Tsuyoshi
    Omatsu, Kohei
    Sakamoto, Kimihiko
    Kawamata, Yasutaka
    Umayahara, Kenji
    Tanaka, Hiroko
    Akiyama, Futoshi
    Takizawa, Ken
    GYNECOLOGIC ONCOLOGY, 2010, 119 (02) : 212 - 216